The loss of ACADIA Pharmaceuticals under GAAP for 9 months of 2020 amounted to $214.824 million, an increase of 17.9% compared to $182.223 million in the previous year. Revenue increased by 33.2% to $320.748 million, compared to $240.75 million a year earlier.
The loss of ACADIA Pharmaceuticals under GAAP for 9 months of 2020 amounted to $214.824 million, an increase of 17.9% compared to $182.223 million in the previous year. Revenue increased by 33.2% to $320.748 million, compared to $240.75 million a year earlier. 
ir.acadia-pharm.com
English (US) 